Autoantibody Profile in Systemic Sclerosis

  • Fatemeh Behmanesh Department of Pediatrics, Ghaem Hospital, Mashhad University of Medical Science, Mashhad, Iran.
  • Reza Amin Department of Immunology and Allergy, Shiraz University of Medical Science, Shiraz, Iran.
  • Mohammad Khajedaluee Department of Community Medicine and Health, Mashhad University of Medical Science, Mashhad, Iran.
  • Marvin J Fritzler Department of Biochemistry and Molecular Biology, School of Medicine, University of Calgary, Canada.
Keywords: Autoantibodies, scleroderma, systemic, nuclear antigens


Systemic sclerosis is a generalized disorder of connective tissue clinically characterized by thickening and fibrosis of the skin and by distinctive forms of involvement of internal organs. One of the hallmarks of systemic sclerosis is the presence of serum autoantibodies against a variety of nuclear and cytoplasmic antigens. The primary purpose of this study was to identify the autoantibodies profile in the scleroderma sera and the secondary goal was to determine the correlation and discrepancy of autoantibody profile. Autoantibody profile was determined in 118 samples stored in the Advanced Diagnostic Laboratory at the University of Calgary. 78 sera were provided from Canadian and 40 sera were provided from Ukraine. We used the following techniques to identify autoantibodies profile in scleroderma patients: 1. Antinuclear antibody (ANA) by indirect immunofluorescence on human epithelial cell substrate 2. Detection and identification of specific autoantibodies by Innolia strip assay 3. Detection and identification of specific autoantibodies against extractable nuclear antigens. 111 out of 118 patients showed positive ANA results by indirect immunofluorescence and 7 patients had negative ANA results. Anti-ENA analyses by Inolia were positive in 84 patients, while by western blotting 81 patients showed positive results. In this study, we compared the results of anti-ENA antibody by Innolia with SLR technique. A significant correlation was found between anti-SCl-70 antibodies (P=0.000) and anti- RNP antibodies (P=0.001) and JO-1 antibodies (P=0.014). Thus, we may propose that SLR and Innolia techniques could be used for the detection of autoantibody in systemic sclerosis.


Seibold JR. Scleroderma and mixed connective tissue diseases. In: Harris ED Jr, Budd RC, Genovese MC, Firestein GS, Sargent JS, editors. Kelley's Textbook of Rheumatology. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005. p. 1211-12.

Black CM, Denton PD. Scleroderma and related disorders in,adults and children. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, editors. Oxford Textbook of Rheumatology. 3rd ed. Oxford: Oxford University Press; 2004. p. 873.

Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA Jr. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospitaldiagnosed cases, 1963-1982. Arthritis Rheum 1997;40(3):441-5.

Mayes MD, Laing TJ, Gillespie BW, Cooper BC, Lacey JV Jr, Hirschenberger WS, et al. Prevalence, incidence and survival rates of systemic sclerosis in the Detroit metropolitan area. Arthritis Rheum 1996;39 Suppl 9:S150.

Silman AJ, Newman J. Epidemiology of systemic sclerosis. Curr Opin Rheumatol 1996;8(6):585-9.

Mayes MD. Epidemiology of systemic sclerosis and relateddiseases. Curr Opin Rheumatol 1997;9(6):557-61.

Medsger TA, Jr, Masi AT. The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chronic Dis 1978;31(2):73-85.

Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA,Kurland LT. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota,1950 through 1979. Mayo Clin Proc 1985;60(2):105-13.

Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI, et al. Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum 1989;32(8):998-1006.

Geirsson AJ, Steinsson K, Guthmundsson S, Sigurthsson V. Systemic sclerosis in Iceland. A nationwide epidemiological study. Ann Rheum Dis 1994;53(8):502-5.

Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S. Clinical implication of autoantibodies in patientswith systemic rheumatic diseases. Expert Rev Clin Immunol 2007;3(5):721-38.

Admou B, Arji N, Seghrouchni F, Missoum H, El Fenniri L, Amghar S, et al. Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases). Ann Biol Clin (Paris) 2007;65(3):291-7.

Tobing M, Darmadi S. Limited systemic sclerosis in a young boy [Online]. 2006. Available from: URL: med=9&bid=3

Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A.The association of antinuclear antibodies with organ involvementand survival in systemic sclerosis. Rheumatology (Oxford) 2003;42(4):534-40.

Sharma VK, Trilokraj T, Khaitan BK, Krishna SM. Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol 2006;72(6):416-20.

Codullo V , Bardoni A, Salvini R, Montecucco C. Antinuclear antibodies in systemic sclerosis. Future Rheumatology 2006;(1)3:365-71.

Shovman O, Gilburd B, Zandman-Goddard G, Yehiely A,Langevitz P, Shoenfeld Y. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases.Autoimmunity 2005;38(1):105-9.

McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989;32(1):54-60.

Basu D, Reveille JD. Anti-scl-70. Autoimmunity 2005;38(1):65-72.

Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis. Wien Med Wochenschr 2008;158(1-2):19-28.

Tamby MC, Bussone G, Mouthon L. Antitopoisomerase 1 antibodies in systemic sclerosis: how to improve the detection?Ann N Y Acad Sci 2007;1109:221-8.

Villalta D, Bizzaro N, Tonutti E, Visentin D, Manoni F, Piazza A, et al. Detection of anti-ENA autoantibodies in patientswith systemic connective tissue diseases. Analyticalvariability and diagnostic sensitivity of 4 methods. RecentiProg Med 1999;90(11):579-84.

Verheijen R, de Jong BA, van Venrooij WJ. A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera. Clin Exp Immunol 1992;89(3):456-60.

Ginsburg WW, Conn DL, Bunch TW, McDuffie FC. Comparison of clinical and serologic markers in systemic lupus erythematosus and overlap syndrome: a review of 247 patients. J Rheumatol 1983;10(2):235-41.

Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006;73(5):490-4.

Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. The prevalenceand clinical significance of anti-U1 RNA antibodiesin patients with systemic sclerosis. J Invest Dermatol2003;120(2):204-10.

Bell S, Krieg T, Meurer M. Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma. Br J Dermatol 1989;121(1):35-41.

Ahmed TA, Malik IA, Saleem M, Khan AA, Hameed A, Shah ST, et al. Antibodies to the extractable nuclear antigens (ENA) in Pakistani patients with systemic rheumatic disease. J Pak Med Assoc 1995;45(1):12-4.

Montecucco C, Bestagno M, Cerino A, Caporali R, Carnevale R, Longhi M, et al. Anti-SSB/La antibodies in Sjögren's syndrome and related autoimmune diseases. Results of a quantitative immunoassay using a highly purified antigen. Clin Exp Rheumatol 1989;7(1):5-11.

How to Cite
Behmanesh F, Amin R, Khajedaluee M, Fritzler MJ. Autoantibody Profile in Systemic Sclerosis. Acta Med Iran. 48(1):12-20.